trending Market Intelligence /marketintelligence/en/news-insights/trending/KxXlZcMevPiOasJQlclLow2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Edwards' new heart implant gets FDA nod amid legal tussle with Boston Scientific

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Edwards' new heart implant gets FDA nod amid legal tussle with Boston Scientific

Edwards Lifesciences Corp.'s heart implant Sapien 3 Ultra system was approved by the U.S. Food and Drug Administration to treat a condition in patients who are at a high risk of open-heart surgery.

The product, an upgraded version of the Sapien valve, is meant to treat patients with aortic stenosis — a condition in which the heart's aortic valve narrows and does not open fully, causing a reduction or blockage in blood flow from the heart to the main artery.

The Irvine, Calif.-based medical device maker said the new system features enhancements on the valve and a new delivery system.

Marlborough, Mass.-based Boston Scientific Corp. says the heart implant infringes on its patents, winning a $35 million award earlier this month after a jury concluded that was the case in the U.S.

However, Edwards does not expect to pay the jury award since the U.S. Patent and Trademark Office invalidated the patent in question earlier this year. In the same ruling, the jury also noted Boston's Lotus heart implant did not infringe on an Edwards patent, which the company plans to appeal.

A court in Germany also made a ruling in favor of Boston Scientific earlier this year, prompting the company to block the sales of Edwards' valve in the country.